ReviewFrontiers in immunology2022

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.

Yuedi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.